Skip to main content

Table 3 Descriptive characteristics for evaluated plasma markers

From: XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

 

N

Mean

Median

SD

Min

Max

Wilcoxon’s p

NO (μmol/L)

Baseline samples

173

261.47

211.80

192.86

8.28

1,567.20

0.89

On-treatment samples*

51

237.09

227.10

140.68

42.69

606.70

 

OPN (ng/mL)

Baseline samples

173

98.68

62.56

89.29

23.12

512.00

0.002

On-treatment samples

51

75.42

54.72

76.32

25.44

507.52

 

TGF-β1(ng/mL)

Baseline samples

173

34.24

20.63

57.07

0.53

662.21

0.025

On-treatment samples

51

28.36

18.80

33.35

3.34

228.33

 

VEGF-A (pg/mL)

Baseline samples

172

122.54

57.85

190.33

15.60

1,601.31

<0.001

On-treatment samples

51

46.79

44.80

21.17

15.60

130.81

 
  1. N, number; SD, standard deviation; Min, minimum level detected; Max, maximum level detected.
  2. *On-treatment samples, at least 3 weeks after treatment initiation.